Blurbs

Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Precigen (PGEN) and BioCardia (BCDA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassava Sciences (SAVAResearch Report), Precigen (PGENResearch Report) and BioCardia (BCDAResearch Report) with bullish sentiments.

Cassava Sciences (SAVA)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Cassava Sciences, with a price target of $180.00. The company’s shares closed last Tuesday at $40.97, close to its 52-week low of $31.44.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 12.1% and a 32.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Cassava Sciences is a Strong Buy with an average price target of $121.50, a 188.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $124.00 price target.

See the top stocks recommended by analysts >>

Precigen (PGEN)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Precigen, with a price target of $13.00. The company’s shares closed last Tuesday at $2.13, close to its 52-week low of $1.91.

According to TipRanks.com, Butler is ranked 0 out of 5 stars with an average return of -4.1% and a 38.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $13.33.

BioCardia (BCDA)

H.C. Wainwright analyst Emanuela Branchetti reiterated a Buy rating on BioCardia today and set a price target of $9.00. The company’s shares closed last Tuesday at $2.08.

Branchetti has an average return of 3.2% when recommending BioCardia.

According to TipRanks.com, Branchetti is ranked #6317 out of 7793 analysts.

BioCardia has an analyst consensus of Strong Buy, with a price target consensus of $5.50, representing a 161.9% upside. In a report issued on February 14, Maxim Group also assigned a Buy rating to the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SAVA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos